Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

HCP Live·Mar 11

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A study has compared the effectiveness of omalizumab and oral immunotherapy (OIT) for treating food allergies. The results suggest that both treatments can enable patients to consume allergenic foods, but there is some uncertainty regarding which treatment is more effective, with some findings indicating omalizumab may be superior or have fewer reactions. The study's findings have been discussed by experts, including Dr. Robert Wood, and have been met with enthusiasm from some families.

Full coverage

Video: Dr Robert Wood on the Benefits of Omalizumab vs OIT for Food Allergies

Pulmonology Advisor·Mar 5

OUtMATCH: Omalizumab and OIT Similarly Enable Allergenic Food Consumption, With Robert Wood, MD

HCP Live·Mar 9

Omalizumab treats multi-food allergy better than oral immunotherapy

National Institutes of Health (NIH) | (.gov)·Mar 3

Johns Hopkins Medicine Study Shows How Recently Approved Drug for Food Allergies Compares to Oral Immunotherapy, Whether It Allows Patients to Eat Their Food Allergens

Johns Hopkins Medicine·Mar 2

Allergists React to Study’s Xolair Vs. OIT Food Allergy Findings

Allergic Living·Mar 4

Families ‘thrilled’ with omalizumab in the year since its approval for food allergy

Healio·Feb 21

A ‘Superior’ Treatment for Food Allergies

Johns Hopkins Medicine·May 22

Xolair Desensitizes Food-Allergic Kids with Fewer Reactions Than OIT

Allergic Living·Feb 14

View original report at HCP Live ↗

Fetching the latest headlines…